Haemonetics HAE Blood Center — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept hae:DepreciationDepletionAndAmortizationNetOfAdjustments.
The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Haemonetics's blood center — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Haemonetics's blood center — D&A?
- Haemonetics (HAE) reported blood center — D&A of $1.79M in Q1 2026.
- How has Haemonetics's blood center — D&A changed year-over-year?
- Haemonetics's blood center — D&A decreased by 28.9% year-over-year, from $2.52M to $1.79M.
- What is the long-term trend for Haemonetics's blood center — D&A?
- Over 2 years (2024 to 2026), Haemonetics's blood center — D&A has grown at a -26.9% compound annual growth rate (CAGR), from $13.39M to $7.16M.
- What does blood center — D&A mean?
- Reflects the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the Blood Center segment. This metric helps investors understand the capital intensity of the segment and the ongoing reinvestment required to maintain operational infrastructure. It is a critical adjustment for calculating cash-based profitability metrics like EBITDA.